Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib + Durvalumab in EGFR T790M+ NSCLC
NCT02454933Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2015
- Primary completion
- Aug 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 3
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2015; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02454933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454933.